ClinicalTrials.gg
CompletedNCT01992874Updated Aug 15, 2017Results posted

Relative Bioavailability of Pimasertib in Cancer Patients

A Phase 1 interventional study of Pimasertib Capsule (Part A) and Pimasertib Tablet (Part A) in Neoplasms, sponsored by EMD Serono. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Neoplasms
  • Pimasertib
  • Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed solid tumors, either to standard therapy or for which no effective standard therapy is available, with a as defined by (RECIST) v1.1
  • An Performance Status (ECOG PS) of less than or equal to (\<=) 1
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Disease conditions or concomitant medication that may significantly influence the conduct of the trial or an abnormal (ECG) or blood pressure at Screening as defined in the protocol
  • Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and including fruit juices or beverages containing these substances
  • History of prior mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or progression of disease on MEK inhibitors
  • Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of RVO
  • of less than 12 weeks
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Pimasertib Capsule/Pimasertib Tablet

    Drug: Pimasertib Capsule (Part A) · Drug: Pimasertib Tablet (Part A) · Drug: Pimasertib Capsule (Part B and trial extension phase)

  • Experimental
    Pimasertib Tablet/Pimasertib Capsule

    Drug: Pimasertib Tablet (Part A) · Drug: Pimasertib Capsule (Part A) · Drug: Pimasertib Capsule (Part B and trial extension phase)

Interventions

  • Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.

    Also known as: AS703026, MSC1936369B

  • Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.

    Also known as: AS703026, MSC1936369B

  • Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.

    Also known as: AS703026, MSC1936369B

  • Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.

    Also known as: AS703026, MSC1936369B

  • DrugPimasertib Capsule (Part B and trial extension phase)

    Drug page: Pimasertib

    Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.

    Also known as: AS703026, MSC1936369B

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) was calculated for Part A Pimasertib 60 mg Capsule and tablet.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  2. Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)

    Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration was at or above the lower limit of quantification.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  3. Apparent Terminal Half-life (t1/2)

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  4. Apparent Total Body Clearance (CL/f)

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  5. Apparent Volume of Distribution (Vz/f)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  6. Terminal Rate Constant (λz)

    Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

  7. Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation

    An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state.

    Time frame: From the first dose of study drug administration until 30 days after the last dose of study drug administration, assessed up to 14 Months

  8. Part B: Number of Subjects Who Experienced Complete Response (CR)

    CR as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 defined as disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (\<)10 millimeter (mm).

    Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

  9. Part B: Number of Subjects Who Experienced Partial Response (PR)

    PR as per RECIST v1.1 defined as 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters.

    Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

  10. Part B: Number of Subjects Who Experienced Stable Disease (SD)

    SD as per RECIST v1.1 defined as neither shrinkage to qualify for PR nor increase to qualify for progressive disease (PD) taking the smallest sum diameters on study as reference. PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; PD = 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.

    Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

  11. Part B: Number of Subjects Who Experienced Progressive Disease (PD)

    PD as per RECIST v1.1 defined as 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.

    Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

07

Results

Posted May 11, 2016

Participant flow

First/last subject (informed consent): Nov 2013/Feb 2015. Clinical data cut-off: May 2014, Study completion date: Feb 2015

Part A
Participant flow — Part A
MilestonePart A: Pimasertib Capsule Then Pimasertib TabletPart A: Pimasertib Tablet Then Pimasertib CapsulePart B:Pimasertib Capsule
Started21170
Completed21170
Not completed000
Part B
Participant flow — Part B
MilestonePart A: Pimasertib Capsule Then Pimasertib TabletPart A: Pimasertib Tablet Then Pimasertib CapsulePart B:Pimasertib Capsule
Started0038
Completed0038
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) was calculated for Part A Pimasertib 60 mg Capsule and tablet.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Part A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Maximum Observed Plasma Concentration (Cmax)254.6 ± 75.7314.1 ± 84.2
SecondaryArea Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)
Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)
h*ng/mLPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)1110.3 ± 74.21109.2 ± 72.9
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hourPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Time to Reach Maximum Observed Plasma Concentration (Tmax)0.750 (0.25 to 4.05)0.517 (0.25 to 3.93)
SecondaryApparent Terminal Half-life (t1/2)
Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Median · hour
Apparent Terminal Half-life (t1/2)
hourPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Apparent Terminal Half-life (t1/2)4.38 (1.65 to 8.15)4.47 (0.71 to 6.21)
SecondaryApparent Total Body Clearance (CL/f)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Geometric mean · liter per hour (L/h)
Apparent Total Body Clearance (CL/f)
liter per hour (L/h)Part A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Apparent Total Body Clearance (CL/f)54.041 ± 74.254.092 ± 72.9
SecondaryApparent Volume of Distribution (Vz/f)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/f)
LiterPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Apparent Volume of Distribution (Vz/f)346.454 ± 54.1334.540 ± 59.0
SecondaryTerminal Rate Constant (λz)
Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Median · 1/h
Terminal Rate Constant (λz)
1/hPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Terminal Rate Constant (λz)0.16 (0.09 to 0.42)0.15 (0.11 to 0.98)
PrimaryArea Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)

Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration was at or above the lower limit of quantification.

Time frame:
Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)
hour*nanogram per milliliter (h*ng/mL)Part A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg Tablet
Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)979.0 ± 76.51060.7 ± 73.0
SecondaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state.

Time frame:
From the first dose of study drug administration until 30 days after the last dose of study drug administration, assessed up to 14 Months
Reported as:
Number · subjects
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
subjectsPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg TabletPart B: Pimasertib Capsule
TEAEs192038
Serious TEAEs1019
TEAEs leading to discontinuation0013
SecondaryPart B: Number of Subjects Who Experienced Complete Response (CR)

CR as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 defined as disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (\<)10 millimeter (mm).

Time frame:
Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Reported as:
Number · subjects
Part B: Number of Subjects Who Experienced Complete Response (CR)
subjectsPart B: Pimasertib Capsule
Part B: Number of Subjects Who Experienced Complete Response (CR)0
SecondaryPart B: Number of Subjects Who Experienced Partial Response (PR)

PR as per RECIST v1.1 defined as 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters.

Time frame:
Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Reported as:
Number · subjects
Part B: Number of Subjects Who Experienced Partial Response (PR)
subjectsPart B: Pimasertib Capsule
Part B: Number of Subjects Who Experienced Partial Response (PR)1
SecondaryPart B: Number of Subjects Who Experienced Stable Disease (SD)

SD as per RECIST v1.1 defined as neither shrinkage to qualify for PR nor increase to qualify for progressive disease (PD) taking the smallest sum diameters on study as reference. PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; PD = 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.

Time frame:
Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Reported as:
Number · subjects
Part B: Number of Subjects Who Experienced Stable Disease (SD)
subjectsPart B: Pimasertib Capsule
Part B: Number of Subjects Who Experienced Stable Disease (SD)10
SecondaryPart B: Number of Subjects Who Experienced Progressive Disease (PD)

PD as per RECIST v1.1 defined as 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.

Time frame:
Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Reported as:
Number · subjects
Part B: Number of Subjects Who Experienced Progressive Disease (PD)
subjectsPart B: Pimasertib Capsule
Part B: Number of Subjects Who Experienced Progressive Disease (PD)15

Adverse events

Collected over Baseline up to end of trial (before the start of a new anticancer therapy or 30 ± 2 days after the last investigational medicinal product administration.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Pimasertib 60 mg Capsule—1/38 (2.6%)18/38 (47.4%)
Part A: Pimasertib 60 mg Tablet—0/37 (0%)17/37 (45.9%)
Part B: Pimasertib Capsule (BID)—19/38 (50%)37/38 (97.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg TabletPart B: Pimasertib Capsule (BID)
DiarrhoeaGastrointestinal disorders1/380/372/38
PyrexiaGeneral disorders1/380/372/38
HypertensionVascular disorders0/380/372/38
HypotensionVascular disorders0/380/372/38
Cardiac failure congestiveCardiac disorders0/380/371/38
Abdominal pain upperGastrointestinal disorders0/380/371/38
Gastrointestinal haemorrhageGastrointestinal disorders0/380/371/38
Rectal haemorrhageGastrointestinal disorders0/380/371/38
Small intestinal obstructionGastrointestinal disorders0/380/371/38
Disease progressionGeneral disorders0/380/371/38
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPart A: Pimasertib 60 mg CapsulePart A: Pimasertib 60 mg TabletPart B: Pimasertib Capsule (BID)
DiarrhoeaGastrointestinal disorders2/386/3722/38
FatigueGeneral disorders2/380/3720/38
Blood creatine phosphokinase increasedInvestigations0/380/3717/38
NauseaGastrointestinal disorders3/382/3713/38
RashSkin and subcutaneous tissue disorders1/381/3713/38
Oedema peripheralGeneral disorders0/380/3710/38
Retinal detachmentEye disorders0/380/379/38
VomitingGastrointestinal disorders1/380/379/38
PyrexiaGeneral disorders1/380/378/38
Vision blurredEye disorders1/384/377/38

Baseline characteristics

Safety analysis set included all subjects who received at least one dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean60.6 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female20
Male18
08

Study locations

1 site
  • Please Contact U.S. Medical Information Located in
    Rockland, Massachusetts, United States
09

References and documents

Publications

  • Mahadevan D, Mita M, Richards D, McClay E, Heist RS, Kumar A, Sundararajan S, Naing A. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. Cancer Chemother Pharmacol. 2017 Apr;79(4):681-688. doi: 10.1007/s00280-017-3258-0. Epub 2017 Mar 13. PubMed 28289865 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in May 2014, 6 months.

Results were first posted in May 2016, 1 year 11 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 6 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 25, 2013
StartActual
Nov 30, 2013
Primary completionActual
May 31, 2014
CompletionActual
Feb 28, 2015
Results first posted
May 11, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01992874
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Nov 30, 2013
Primary completion
May 31, 2014
Completion
Feb 28, 2015
Results posted
May 11, 2016
Last update
Aug 15, 2017

Study contacts

Medical Responsible
study director · EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion